Coro de la Pontificia Universidad Católica de Puerto Rico

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

Retrieved on: 
Thursday, January 26, 2023

“We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.

Key Points: 
  • “We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.
  • Development of scaled-up (kg batch size) manufacturing of BetterLife’s proprietary form of 2-bromo-LSD (“BETR-001”) using BetterLife’s proprietary synthetic pathway.
  • The starting material and whole synthetic pathway do not involve any controlled substance and, therefore, are not bound by controlled substance regulations.
  • Scientific presentations on BETR-001 preclinical data were made at the following conferences:
    Canadian Association for Neuroscience (CAN) / May 12-15, 2022 / Toronto, Canada.

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Retrieved on: 
Tuesday, July 19, 2022

This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.

Key Points: 
  • This clinical trial aims to evaluate the immunogenicity and safety of the quadrivalent influenza vaccine among individuals aged 3 and above.
  • In total, there will be 1,600 volunteers recruited, half of whom will receive 1 dose of SINOVACs inactivated quadrivalent influenza vaccine, and the other half will receive a different quadrivalent influenza vaccine commercially available in Chile.
  • Children aged between 3 and 8 of both groups who havent received any influenza vaccine will receive 2 doses of influenza vaccine.
  • The upcoming clinical trial in Chile will provide further evidence on the efficacy and safety of SINOVACs quadrivalent influenza vaccine.

President of Chile Appoints New Director of InvestChile

Retrieved on: 
Wednesday, April 6, 2022

SANTIAGO, Chile, April 06, 2022 (GLOBE NEWSWIRE) -- The President of Chile, Gabriel Boric, has appointed economist Karla Flores Mardones as the new managing director of InvestChile, the public agency that promotes foreign investment in the country.

Key Points: 
  • SANTIAGO, Chile, April 06, 2022 (GLOBE NEWSWIRE) -- The President of Chile, Gabriel Boric, has appointed economist Karla Flores Mardones as the new managing director of InvestChile, the public agency that promotes foreign investment in the country.
  • Flores is an economist from the Pontificia Universidad Catlica de Chile and holds a master's degree in Applied Macroeconomics from the same university.
  • Karla Flores is the first woman to hold the position of InvestChiles managing director since its foundation in 2016.
  • The Government is grateful to the former managing director of InvestChile, commercial engineer Andrs Rodrguez Rowe, for his work.

Dr. Eleanor Fish, Advisory Board Member, Awarded Order of Canada

Retrieved on: 
Thursday, January 6, 2022

The Order of Canada is how Canada honours people who make extraordinary contributions to the nation.

Key Points: 
  • The Order of Canada is how Canada honours people who make extraordinary contributions to the nation.
  • Dr.
  • Fish was bestowed this order for her contributions to immunology, including her groundbreaking studies on the use of interferon-alpha in the treatment of disease.
  • Dr.

BetterLife Successfully Completes Phase 1 and Initiates Phase 2 Clinical Trials with Interferon Alpha-2b in COVID-19 Patients in Chile

Retrieved on: 
Monday, November 29, 2021

Eighteen healthy subjects were enrolled in the Phase 1 portion of the IN2COVID trial (ClinicalTrials.gov Identifier: NCT04988217 ).

Key Points: 
  • Eighteen healthy subjects were enrolled in the Phase 1 portion of the IN2COVID trial (ClinicalTrials.gov Identifier: NCT04988217 ).
  • AP-003 demonstrated an excellent safety and tolerability profile and no serious adverse events were observed.
  • Dr. Eleanor Fish, one of the Principal Investigators of the trial, commented, I am confident that inhaled administration of interferon alpha-2b, AP-003 will prove to be an effective treatment against COVID-19.
  • With AP-003, there is the added advantage of a pathogen agnostic broad spectrum antiviral that may have therapeutic benefits for many respiratory virus infections.

Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN⍺2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2

Retrieved on: 
Tuesday, October 12, 2021

Previously, BetterLifes rhIFN2b showed potent activity against the Wuhan reference strain, Alpha (B.1.1.7, UK), and the Beta (B.1.351, South Africa) variants.

Key Points: 
  • Previously, BetterLifes rhIFN2b showed potent activity against the Wuhan reference strain, Alpha (B.1.1.7, UK), and the Beta (B.1.351, South Africa) variants.
  • We are very pleased to see the early preclinical data confirming the high anti-viral activity of BetterLifes rhIFN2b against this variant of concern.
  • The trial tests BetterLifes proprietary inhaled rhIFN2b product, AP-003, versus placebo in early stage COVID-19 patients (
  • His research focuses on the complex virus-host interactions of emerging viral pathogens, with a focus on the host interferon response.